Randomized Trial of TAVI vs. SAVR in Patients With Severe Aortic Valve Stenosis at Intermediate Risk of Mortality

  • End date
    Mar 22, 2027
  • participants needed
  • sponsor
    Universitätsklinikum Hamburg-Eppendorf
Updated on 22 September 2021
heart disease
angina pectoris
aortic valve stenosis
aortic valve replacement
transcatheter aortic valve implantation
valvular disease


Randomized controlled, multi-center trial randomizing patients with symptomatic severe aortic stenosis at low to intermediate operative risk of mortality in a 1:1 fashion to transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) to test, whether TAVI is non-inferior to SAVR, as measured by all-cause mortality or stroke after 1 and 5 years.


A paradigm-shift towards performing TAVI in intermediate- and low-risk patients has already begun, as procedural results of TAVI have improved significantly within the past years. Nevertheless, a prospective and independent comparison of surgical (SAVR) and interventional (TAVI) valve therapy in patients considered at low to intermediate risk that covers an "all-comers" patient population and multiple devices has not yet been performed.

The DEDICATE-trial is designed as a prospectively randomized (1:1), multi-center, comparator-controlled interventional trial to investigate whether transcatheter aortic valve implantation (TAVI) is non-inferior - as measured by all-cause mortality or stroke after 1 and 5 years - compared to surgical aortic valve replacement (SAVR) in the treatment of patients with symptomatic severe aortic stenosis at low to intermediate operative risk of mortality, as assessed by the local Heart Team.

Condition Aortic Stenosis, VALVULAR HEART DISEASE, Heart Valve Disease, aortic valve stenosis
Treatment Surgical aortic valve replacement, Transcatheter Aortic Valve Implantation
Clinical Study IdentifierNCT03112980
SponsorUniversitätsklinikum Hamburg-Eppendorf
Last Modified on22 September 2021


Yes No Not Sure

Inclusion Criteria

Heart team consensus that TAVI and SAVR are both medically justified and advisable based on
Degenerative aortic valve stenosis with echocardiographically derived criteria
Mean gradient >40 mmHg or
Jet velocity greater than 4.0 m/s or
Aortic valve area (AVA) of < 1.0 cm2 (indexed effective orifice area < 0.6cm2/m2)
Patient is symptomatic from his/her aortic valve stenosis
New York Heart Association Functional Class II or
Angina pectoris or
Patient is classified as low to intermediate operative risk as assessed by the local heart team according to the variables outlined in the 2017 ESC/EACTS Guidelines for the Management of valvular heart disease, taking into account cardiac and extracardiac Patient characteristics and established risk scores (e.g. STS-PROM, EuroSCORE)
A transfemoral or alternative (e.g. transapical, transaortic, transaxillary) access for TAVI seems feasible. Centers should follow a "transfemoral first" strategy for the primary route of access; however, other routes of access are also allowed, as decided by local heart team consensus
Patient has provided written informed consent to participate in the trial
Ability of the patient to understand the patient information and to personally sign and date the informed consent to participate in the study, before performing any study related procedures
The patient agrees to undergo SAVR, if randomized to control treatment
The patient and the treating physician agree that the patient will return for all required post-procedure follow-up visits
Patients aged 65 to 85 years
Male patients or females who are postmenopausal defined as no menses for 12 months without an alternative medical cause

Exclusion Criteria

Aortic valve is a congenital unicuspid or congenital bicuspid valve, or is non-calcified
Untreated clinically significant coronary artery disease considered a contraindication to an isolated aortic valve procedure (TAVI or SAVR) according to heart team consensus
Previous cardiac surgery
Any percutaneous coronary intervention performed within 1 month prior to the study procedure
Untreated severe mitral or tricuspid regurgitation
Untreated severe mitral stenosis
Hemodynamic instability requiring inotropic support or mechanical circulatory support
Ischemic stroke or intracranial bleeding within 1 month
Severe ventricular dysfunction with left ventricular ejection fraction < 20% as measured by resting echocardiogram
Hypertrophic obstructive cardiomyopathy or severe basal septal hypertrophy with outflow gradient
Echocardiographic evidence of an intracardiac mass, thrombus, vegetation or endocarditis
Any other condition considered a contraindication for an isolated aortic valve procedure
Symptomatic carotid or vertebral artery disease
Expected life expectancy < 12 months due to associated non-cardiac comorbidities
Currently participating in another investigational drug or device trial
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note